Cadrenal Therapeutics
CVKD
10 hedge funds and large institutions have $1.04M invested in Cadrenal Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
154% more capital invested
Capital invested by funds: $408K → $1.04M (+$628K)
67% more funds holding
Funds holding: 6 → 10 (+4)
0.42% more ownership
Funds ownership: 0.28% → 0.71% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$791K |
| 2 |
Renaissance Technologies
New York
|
+$58.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$47.2K |
| 4 |
VF
Virtu Financial
New York
|
+$27.4K |
| 5 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$23.9K |
Top Sellers
CVKD Hedge Fund Activity: Q1 2024 in Review
10 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q1 2024, worth a combined $1.04M — up 154% from $408K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CVKD positions and 0 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, adding an estimated $791K.
- 10 institutional investors held Cadrenal Therapeutics (CVKD) as of Q1 2024, up from 6 in Q4 2023.
- Funds reported $1.04M of Cadrenal Therapeutics stock for Q1 2024, up 154% quarter-over-quarter.
- 4 funds opened new Cadrenal Therapeutics positions in Q1 2024 and 0 closed out, a net change of +4 holders.
- The largest Cadrenal Therapeutics buyer in Q1 2024 was Armistice Capital, an estimated $791K added.
Based on aggregated 13F filings for Q1 2024.